Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting.

Heather E Danysh Catherine B Johannes Daniel C Beachler J Bradley Layton Ryan Ziemiecki Alejandro Arana Jade DinhLing LiBrian Calingaert Manel Pladevall Phillip R HuntHungta ChenCecilia KarlssonKristina JohnssonAlicia W Gilsenan

Published in: Drug safety (2022)

These real-world studies do not suggest increased risks of hALI or sUTI, and they suggest a potential decreased risk of sUTI with dapagliflozin exposure compared with other GLDs.

Keyphrases

drug induced
liver injury
urinary tract infection
case control
human health
liver failure
risk factors
early onset
risk assessment
intensive care unit
climate change